Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica, Inc. (BMRA)
NASDAQ:AMEX Investor Relations:
biomerica.com/company/investor.asp
Company Research
Source: GlobeNewswire
Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the second quarter, Biomerica entered into a marketing services agreement with Henry Schein to support the commercialization of the Company’s inFoods® IBS test in the United States. In addition, inFoods® IBS was featured in a Henry Schein publication highlighting a precision-based approach to the management of Irritable Bowel Syndrome. Together, these initiatives expand awareness of inFoods® IBS among healthcare providers and support broader adoption of the test in clinical practice. 2.Biome
Show less
Read more
Impact Snapshot
Event Time:
BMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRA alerts
High impacting Biomerica, Inc. news events
Weekly update
A roundup of the hottest topics
BMRA
News
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test [Yahoo! Finance]Yahoo! Finance
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS TestGlobeNewswire
- Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio [Yahoo! Finance]Yahoo! Finance
- Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test PortfolioGlobeNewswire
- Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS [Yahoo! Finance]Yahoo! Finance
BMRA
Sec Filings
- 1/14/26 - Form 10-Q
- 12/31/25 - Form 4
- 12/31/25 - Form 4
- BMRA's page on the SEC website